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Abstract
Introduction: Inappropriate Notch signaling, downstream of g-secretase activity, is understood to have tumor-
promoting function and to be associated with poor outcome in cancer, of the breast in particular. The molecular
basis of antitumoral effects of its inhibitors, however, remains poorly characterized. Moreover, the effects of their
combination with the pro-apoptotic pharmacologic inhibitor of Bcl-2/Bcl-xL, ABT-737, have never been evaluated.
In this study, we thus specifically addressed the biologic consequences of targeting g-secretase and Bcl-2/Bcl-xL,
alone or simultaneously, in breast cancer cell lines as well as in a novel human breast cancer ex vivo assay.
Methods: By using in vitro 2D or 3D cultures of breast cancer cells plus a novel preclinical short-term ex vivo assay
that correctly maintains human mammary tissue integrity and preserves tumor microenvironment, we tested the
effects of the pharmacologic g-secretase inhibitor GSIXII used as a single agent or in combination with ABT-737.
Results: We show herein that the g-secretase inhibitor, GSIXII, efficiently induces apoptosis in breast cancer cell lines by
a process that relies on the induction of Noxa, a pro-apoptotic Bcl2-homology 3 domain (BH3)-only protein of the Bcl-2
family that functions as an inhibitor of antiapoptotic Mcl1. GSIXII also targets mammary cancer stem-like cells because it
dramatically prevents in vitro mammosphere formation. Moreover, combining GSIXII treatment with ABT-737, a BH3-
mimetic inhibitor of additional antiapoptotic proteins, such as Bcl-2 and Bcl-xL, leads to both a synergistic apoptotic
response in breast cancer cells and to an inhibitory effect on mammosphere formation. These effects are also found
when a Notch transcriptional inhibitor, SAHM1, is used. Finally, we evaluated individual human tumor responses to g-
secretase inhibition alone or in combination with ABT-737 in ex vivo assays. Analysis of a series of 30 consecutive
tumors indicated that a majority of tumors are sensitive to apoptosis induction by GSIXII and that association of GSIXII
with ABT-737 leads to an enhanced induction of apoptosis in tumor cells.
Conclusions: We thus provide evidence that g-secretase, and downstream Notch signaling, are relevant targets in
breast cancer. GSIXII, used as single agent or in combination with clinically relevant BH3-mimetics, is a promising
innovative proapoptotic strategy to treat mammary tumors.
Introduction
Notch signaling impinges on a wide variety of cellular
processes, including cell-fate specification, cell prolifera-
tion, differentiation, apoptosis, and maintenance of stem
cells. Deregulation of Notch signaling leads to several
pathologic conditions, including cancer [1]. Notch was
first identified as an oncogene in T-acute lymphoblastic
leukemia with (7,9) chromosomal translocation [2] or
activating mutation within Notch1 gene [3]. The Notch
pathway also participates in oncogenesis through aber-
rant activation related to deregulated expression of
Notch receptors or ligands, or the loss of a negative reg-
ulator, as described for Numb. Such inappropriate acti-
vation of the Notch pathway has been reported in many
solid tumors, including breast cancer, in which it was
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linked to poor clinical outcomes [4-6]. Of note, the
Notch pathway may have a direct oncogenic effect by its
aberrant activation in cancer but may also be involved
in feedback-reactivation process after conventional
anticancer therapy, thus participating in chemoresis-
tance. Indeed, this pathway is turned on in breast cancer
cells, on tamoxifen treatment of estrogen receptor (ER)-
positive tumors [7,8], or after HER2 inhibition in HER2-
amplified tumors [9]. This is due to the capacity of
estradiol or the HER2 pathway intrinsically to inhibit
Notch activity. Another important point is that the
mammary microenvironment can trigger Notch para-
crine signaling to mammary cells, making a potent
niche for mammary stem cells [10,11].
After ligand binding to Notch transmembrane recep-
tors, a series of proteolytic reactions leads to the release
of Notch intracellular domain (NICD), allowing its
translocation into the nucleus, where it interacts with
DNA-bound protein factor CSL (or CBF1) and recruits
MAML family member coactivators, such as MAML1.
These events lead to the formation of a trancriptional
activator complex that drives the transcription of tar-
geted genes [12].
The final proteolytic cleavage step mediated by the
g-secretase complex is critical for Notch-signaling acti-
vation, and its inhibition can be exploited through emer-
ging pharmacologic drugs identified as g-secretase
inhibitors (GSIs). These new agents attenuate signaling
from all four receptors and are being investigated as
candidates in cancer therapy. Recent studies provided
evidence that GSI treatment suppressed growth of
breast cancer cells, increasing the interest in validating
this novel therapeutic approach [13-16].
A better understanding of molecular mechanisms
involved in the antitumoral effect of Notch inhibition is
needed to develop a comprehensive use of Notch inhibi-
tors such as GSI. g-Secretase activity and Notch signaling
appear to be critical for cell survival [17,18], but evaluat-
ing how exactly their inhibition affects survival pathways
in cancer cells remains to be performed. Along this line,
it must be noted that the effects of g-secretase inhibition
have not been systematically assessed. In particular, their
effects on intact human tumors in the presence of their
microenvironment have not been evaluated. Aberrant
survival signaling is a frequent feature of cancer cells, in
part due to the acquisition of an increased apoptotic
threshold leading to tumor chemoresistance [19]. This
process often arises from the deregulation of Bcl-2 family
members. This family is divided into three categories, (a)
the antiapoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1); (b)
the proapoptotic BH3-only proteins, such as Noxa,
Puma, and Bim; and (c) the proapoptotic multidomain
proteins (Bax, Bak) that function downstream of the for-
mer. This family of proteins maintains a subtle survival/
cell-death balance by regulating mitochondrial integrity,
caspase activation, and consequent cell demolition. Anti-
apoptotic proteins promote survival, in great part, by
physically interacting with the BH3 domain of their proa-
poptotic counterparts via a well-characterized binding
interface. Subtle yet significant differences exist in the
BH3-binding interface of each Bcl-2 homologue, so that
promiscuous but also selective interactions occur
between these proteins and multidomain or BH3-only
proteins. For instance, Bim or Puma interacts with all
known Bcl-2 homologues, whereas Bad interacts prefer-
entially with Bcl-2 and Bcl-xL, and Noxa, with Mcl-1
[20]. Thus, Bcl-2 homologues exert complementary
effects on cell survival, and their simultaneous inhibition
is expected to promote efficient cancer cell death.
The pivotal role of the Bcl-2 family in the apoptotic
pathway has stimulated considerable interest in develop-
ing anticancer agents that specifically act to restore
apoptotic cell death [21]. The BH3 mimetic, ABT-737,
is a promising compound that potently binds to and
neutralizes the prosurvival proteins Bcl-2, Bcl-xL, and
Bcl-w, but not Mcl-1 or A1 [22]. Thus, expression of
Mcl-1 confers resistance to ABT-737 when used as sin-
gle agent and, conversely, approaches that lead to down-
regulation or inhibition of Mcl-1 are expected to
enhance sensitivity to this compound.
Based on these premises, we investigated the impact of
Notch inhibition on the apoptotic threshold in breast can-
cer cells, by focusing our analysis on the Bcl-2 family of
proteins. We first pointed out that the g-secretase inhibitor
GSIXII, used as single agent, triggers apoptosis in vitro in
breast cancer cells. It also exerts an inhibitory effect on
breast cancer cells that have a stem-like phenotype, as
does the Notch transcriptional inhibitor SAHM1. Impor-
tantly, GSIXII treatment also induced an apoptotic
response in numerous intact breast tumors tested in an ex
vivo assay developed in our laboratory. We further demon-
strated that the GSIXII apoptotic effect depended mainly
on the induction of Noxa, a BH3-only protein that inhibits
Mcl-1. Consistently, GSIXII treatment combined with Bcl-
2/Bcl-xL inhibition by ABT-737 potently enhanced the
proapoptotic response of the breast cancer cells, including
in ex vivo specimens. Thus, our results highlight the clini-
cal relevance of targeting g-secretase and downstream
Notch signaling in breast cancer, especially in combination
with the Bcl-2/Bcl-xL inhibitor ABT-737.
Materials and methods
Reagents and cell lines
MCF7, BT549, MDAMB231, ZR75.1, and T47D cell
lines were from American Type Culture Collection, and
Cal51, from DSMZ (Braunschweig, Germany). All cell
lines were cultured by following the suppliers’
recommendations.
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SAHM1 and g-secretase inhibitor XII (GSIXII, z-Ile-
Leu-CHO) were purchased from Calbiochem (Darmstadt,
Germany, Bortezomib and ABT-737 from Selleck Chemi-
cals (Houston, TX, USA), and the pan-caspase inhibitor
QVD-OPH, from R&D Systems (Abingdon, UK). Antibo-
dies against cleaved Notch1 (N1ICD) were purchased
from Cell Signaling (Saint Quentin en Yvelines, France);
Puma, from Epitomics (Nanterre, France); and Bim and
Noxa, from AbCam (Cambridge, UK). Antibodies to Bax
and Actin were from Dako (Trappes, France) and Milli-
pore, (Molsheim, France) respectively. Antibody against
cleaved (that is, activated) caspase-3 used in IHC was from
BD Bioscience (le Pont de Claix, France).
Apoptosis assays
Cell death was assessed with Apo2.7 (Beckman Coulter,
Villepinte, France) staining and confirmed by an Annexin-
V binding assay (Beckman Coulter, Villepinte, France),
performed according to manufacturer’s instructions. Flow-
cytometry analysis was performed on a FACSCalibur by
using the CellQuestPro software.
Mammosphere-formation assay
MCF7 or BT549 cells treated with the indicated treat-
ment or siRNA were plated as single cells in ultra-low-
attachment plates (Corning, Avon, France) at low density
(500 viable cells/cm2). They were grown in serum-free
mammary epithelial cell growth medium containing
DMEM-F12 (Sigma, Saint-Quentin Fallavier, France)
supplemented with B27 (Gibco, Saint Aubin France) and
MEGM singlequots (Lonza, Levallois-Perret, France), as
previously described [23]. Mammosphere-forming units
(MFUs) were counted as the number of mammospheres
≥ 50 μm. Mammosphere formation of the second and
third generations was investigated in the presence of
GSIXIII, or not, after trypsin treatment of the first- and
second-generation mammospheres, respectively.
Immunoblot analysis
Patient samples for immunoblots were snap-frozen into
liquid nitrogen and then prepared according to [24].
Cell-lines samples were prepared as previously described
[25]. Fifty micrograms of protein was loaded for each
lane and separated by 10% or 12.5% SDS-PAGE, then
electrotransfered to PVDF membranes. Western blot
analysis was performed by standard techniques with ECL
detection (Pierce, IllKirch, France).
RNA interference
Cells were transfected by using Lipofectamine RNAiMax
2000 (Invitrogen), according to the manufacturer’s
instructions. Medium was changed 6 hours later, and
compounds were added after 24 hours. The following
siRNAs were used: control siRNA (sc44230) from Santa
Cruz, siRNA Bim (6461) from Cell Signaling, siRNA
Puma from Dharmacon (Lafayette, USA), siRNA Noxa
(AC2Z4U4) from Ambion (Saint Aubin, France), and
siRNA Bax from IDT (Leuven, Belgium).
Quantitative PCR
Total RNA was isolated from cell lines with RNeasy Plus
mini kit (Qiagen, France). The quality of the RNAs was
assessed by analysis of the 28S:18S rRNA ratio by using
the RNA 6000 Nano Assay kit and the Agilent 2100 bioa-
nalyzer (Agilent Biotechnologies). Then 500 ng of total
RNA was reverse transcribed by using the superscript III
reverse transcriptase and random hexamers (Life Technol-
ogies, Saint Aubin, France). Quantitative PCR was done by
using the Maxima SYBR Green/ROX qPCR Master Mix
(Life Technologies) and the MX4000 instrument (Strata-
gene, Basel, Switzerland), according to the manufacturer’s
instructions. To control the specificity of the amplified
product, a melting-curve analysis was done. No amplifica-
tion of unspecific product was observed. Primer sequences
were 5’-GCTGGAAGTCGAGTGTGCTA-3’ (forward)
and 5’-CCTGAGCAGAAGAGTTTGGA-3’ (reverse) for
Noxa. RPLPO AACCCAGCTCTGGAGAAACT (forward)
and CCCCTGGAGATTTTAGTGGT (reverse), HPRT1
5’-ATGCTGAGGATTTGGAAAGG-3’ (forward) and 5’-
GATGTAATCCAGCAGGTCAGC-3’ (reverse) and
RSP18 5’-ATCCCTAAAAGTTCCAG-3’ (forward) and 5’-
CCCTCTTGGTGAGGTCAA-3’ (reverse) were used for
normalization. Relative quantification was carried out by
using the ΔΔCt method.
Promoter-reporter activity assay
The ability of NICD to bind to CBF1 and activate gene
transcription was measured by the transfection of lucifer-
ase reporter plasmids that contain four copies of a binding
site for CBF1 (CBF1-Luc) or mutated CBF1 (mCBF1-Luc)
that were a kind gift from Dr. Diane Hayward (Johns Hop-
kins University, Baltimore, MD, USA) [26]. Cells were
transfected by using Lipofectamine 2000 (Invitrogen).
Medium was changed 6 hours later, and treatment was
added after 24 hours. Cells were harvested 48 hours after
transfection and analyzed by using the Stop&Glow kit
(Promega, Lyon, France) and following the manufacturer’s
instructions. Results were expressed as ratios between the
CBF1-Luc-transfected samples and the mCBF1-Luc-trans-
fected one for each cell line in each condition, in three
independent experiments.
Lentiviral infection
Recombinant lentivectors were produced by transient
transfection of the transducing vector into 293T cells
with two packaging vectors: pMD.G, a plasmid expres-
sing the VSV-G envelope gene (Addgene plasmid 12259,
Addgene, Cambridge, MA), and pCMVDeltaR8.91, a
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plasmid expressing the HIV-1 gag/pol, tat, and rev genes
(Addgene plasmid 8455) associated with a GFP control
plasmid (Addgene plasmid 17618) or plasmid coding for
N1ICD and GFP with two independent internal promo-
ters (Addgene plasmid 17626), as described previously
[27]. Cells were infected for 24 hours before treatment
with GSIXII for 48 hours, and apoptosis was assessed on
GFP+ cells by using Apo2.7 staining followed by flow-
cytometry analysis.
Preclinical breast cancer ex vivo assay
Fresh human mammary samples were obtained from
patients with invasive carcinoma after surgical resection
at the Institut de Cancérologie de l’Ouest, René Gaudu-
cheau, Nantes, France. As required by the French Com-
mittee for the Protection of Human Subjects, informed
consent was obtained from study patients to use their
surgical specimens and clinicopathologic data for
research purposes, and the local ethics committee
approved protocols.
The tumors were cut into thin slices (250 μm) by using a
vibratome (Microm International, ThermoFischer Scienti-
fic, Illikirch, France) and incubated for 48 hours with or
without 15 μM GSIXII. Slices were then fixed in 10%
buffered formalin and were paraffin embedded. Sections (3
μm) were then cut for standard histologic analysis assessed
by hematoxylin-eosin-saffron (HES) coloration. Immuno-
histochemistry (IHC) was performed to assess tumoral cell
apoptosis with cleaved caspase-3 antibody. In brief, after
deparaffinization in xylene and rehydration, endogenous
peroxidase activity was blocked with 3% hydrogen perox-
ide. Samples were steamed for antigen retrieval with
citrate buffer (pH 6.0). Slides were incubated for active
caspase-3 (clone C92-605, dilution 1:1,200) on an auto-
mated immunostainer (Autostainer Plus, Dako) by using a
standard labeled streptavidin-biotin method (Dako, LSAB
+, Dako REAL Detection Systems kit) followed by 3,3’-dia-
minobenzidine chromogen detection. Immunostained
slides were counterstained with hematoxylin (Dako,
Trappes, France). Negative controls (omission of the pri-
mary antibody) were included in each run. Active caspase-
3 immunostained cells were assessed according the per-
centage of labeled cells in 200 carcinomatous cells
counted. Nonneoplastic cells were excluded from
counting.
Statistical analysis
Statistical analysis was performed by using a one-tailed
paired Student t test and one-way ANOVA test on
GraphPad Prism. Errors bars represent standard errors
of the mean (SEM). The symbols correspond to a P
value inferior to *0.05, **0.01, or ***0.001, and ns for not
statistically significant.
Results
Notch inhibition induced growth arrest and cell death in
breast cancer cells
To investigate the proapoptotic effects of the g-secretase
inhibitor GSIXII and to define the range of active con-
centrations, we treated the breast cancer cell line
MDAMB231 with increasing concentrations (4 to
20 μM) for 48 hours before evaluation of apoptosis by
measuring the expression of Apo2.7 antigen (whose
expression is restricted to dying cells) by using flow-
cytometry analysis. In comparison to DMSO (mock)
treatment, GSIXII treatment induced specific apoptosis,
and concentrations from 8 μM to 15 μM triggered
increasing cell death (Figure 1A). The concentration of
15 μM, corresponding to a plateau (inducing 40% of
apoptotic cells), was used. We further tested a panel of
six human breast cancer cells lines either expressing
estrogen receptor (ER+) (ZR75.1, T47D and MCF7) or
not (ER-, without amplification of the HER2 oncogene)
(BT549, Cal51, MDAMB231), for their cell-death
response to this treatment (Figure 1B). All of them
showed significant sensitivity to GSIXII. Interestingly,
ER-/HER2- cell lines exhibited higher sensitivity to
GSIXII (40% versus 20% in ER+ cell lines), as previously
observed by Lee et al. [15]. Apoptotic response to
GSIXII treatment was further confirmed by Annexin-V
binding assay, as shown for BT549, MDAMB231, and
MCF7 cell lines in Additional file 1.
Numerous observations confirmed that GSIXII
potently triggered an apoptotic response in breast can-
cer cells through inhibition of Notch activity in the
breast cancer cells used.
First, we evaluated, with immunoblot analysis, the
expression of the active form of Notch1, N1ICD, in
GSIXII-treated cells compared with control cells, and
found that GSIXII treatment downregulated N1ICD
expression (Figure 2A).
Second, we measured Notch transcriptional activity,
with a Notch promoter luciferase assay containing CBF1
or mutated CBF1 boxes, and this assay pointed out the
efficient inhibition of Notch-driven luciferase transcrip-
tion on GSIXII treatment (Figure 2B).
Third, overexpression of the human N1ICD obtained
by lentiviral infection efficiently protected breast cancer
cells from GSIXIII-induced apoptosis (Figure 2C). Alto-
gether, these results indicate that GSIXII potently inter-
fered with Notch activity, and that this effect
contributed in its impact on cell survival.
g-Secretase inhibitors may also inhibit proteasome
activity, and this effect might contribute to their biologic
activity. We thus compared the effects of GSIXII and
the well-known proteasome inhibitor bortezomib on
both proteasome activity and cell survival. These assays
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showed that GSIXII had a significant effect on protea-
some activity (see Additional file 2A). However, bortezo-
mib treatment that recapitulated this effect did not
promote cell death, in contrast to treatment with GSXII
(see Additional file 2B). The lack of correlation between
inhibition of proteasome activity and apoptotic activity
in these assays indicates that apoptosis induction by
GSIXII cannot solely rely on its ability to inhibit protea-
some activity, even though we cannot formally rule out
that this effect contributes to cell-death induction.
GSI treatment triggered Noxa-dependent apoptosis in
breast cancer cells
The proapoptotic effects of GSIXII were strongly pre-
vented by co-treatment with the chemical pancaspase-
inhibitor QVD-OPH in all breast cancer cell lines (as
shown for three of them in Figure 3A). As Bax is a
major actor in the onset of apoptosis by the mitochon-
drial pathway, the impact of its knockdown by RNA
interference on GSIXII induction of cell death was eval-
uated. Results shown in Figure 3B indicate that siRNA
targeting Bax significantly preserved breast cancer cells
from the deleterious effects of GSIXII. Thus, GSIXII-
induced apoptosis appears to occur mainly through the
canonic mitochondria-dependent pathway requiring Bax
and caspase activation.
To investigate further the molecular pathways involved in
GSIXII induction of cell death, we performed siRNA-based
experiments against Noxa, Bim, or Puma before treating
cells with GSIXII. Of major importance, the sole depletion
of Noxa by RNA interference led to decreased cell sensitiv-
ity to GSIXII in all cell lines tested (Figure 4A and Addi-
tional file 3A). In contrast, neither Puma nor Bim depletion
had a significant impact on the cell-death response to
GSIXII. Of note, protection against cell death by Noxa
knockdown was not complete, but this might rely on resi-
dual partial Noxa expression after Noxa siRNA treatment
(see Additional file 3B). Thus GSIXII induces cell death
preferentially by a Noxa-dependent cell-death pathway.
We then assessed the expression of the BH3-only
proapoptotic proteins, Bim, Puma, and Noxa, with
immunoblot analysis on treatment with GSIXII. In all
breast cancer cell lines, a strong induction of Noxa pro-
tein expression was evidenced in response to GSIXII
treatment (Figure 4B). In contrast, Puma or Bim expres-
sion was not enhanced (as shown in MDAMB231 in
Additional file 4). The better to understand the mechan-
isms involved in Noxa protein accumulation on GSIXII
treatment, RTqPCR analysis was performed to quantify
Noxa mRNA. Data indicated that GSIXII induced Noxa
mRNA, arguing for regulation of Noxa expression at a
transcriptional level (Figure 4C).
GSIXII treatment strongly impaired in vitro mammosphere
formation
Transformed mammary epithelial cells, including estab-
lished breast cancer cell lines, exhibit an inherent
phenotypic plasticity and harbor a subpopulation of can-
cer-initiating cells with features resembling these of
stem cells. The latter cells, which are characterized by
numerous criteria, including their ability to form spheri-
cal colonies in nonadherent fetal bovine serum-free cul-
ture conditions (mammospheres), were frequently
described as being resistant to cell-death induction by
numerous stimuli, and they may therefore rely on survi-
val signals distinct from the bulk population. Moreover,
the Notch pathway might be involved in cell stemness.
We thus evaluated whether GSIXII treatment had an
impact on mammosphere formation by breast cancer cell
lines and whether this relied on cell-death induction.
A dramatic decrease in mammosphere formation was
observed after GSIXII treatment of MCF7 or BT549 cell
lines compared with mock-treated cells (Figure 5A). This
effect was recapitulated by the SAHM1 cell-permeable
peptide (a dominant-negative fragment of MAML1 that
A 
B 
Figure 1 GSIXII induced apoptosis in ER+ or ER-/HER2- breast
cancer cell lines. (A) MDAMB231 cells were treated with increasing
GSIXII doses and analyzed with flow cytometry after Apo2.7
immunostaining. Data represent (percentage of Apo2.7-positive cells)
and the means ± standard errors (SEM) of three independent
experiments. (B) Three ER+ human breast cancer cell lines (ZR75.1,
T47D, and MCF7) and three ER-/HER2- (BT549, Cal51, and MDAMB231)
were treated with GSIXII, 15 μM, for 48 hours and then analyzed with
flow cytometry after Apo2.7 immunostaining. Represented data are
the means ± SEM of three independent experiments.
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specifically prevents assembly of the active transcriptional
complex and blocks Notch transcription activity [28]),
used at 20 μM (Figure 6C). In addition, GSIXII not only
inhibited first-generation mammosphere formation but
also decreased the mammosphere formation of second
and third generations (Figure 5B), which are further
enriched in self-renewing cells. This argues that the treat-
ment affects not only cells that can give progeny, but also
cells that can self-renew. Of importance, Noxa depletion
by RNA interference combined with GSIXII treatment
partially but significantly rescued mammosphere forma-
tion (Figure 5C). Thus, GSIXII potently prevents mam-
mosphere formation, and this effect relies, at least in
part, on Noxa-dependent cell-death mechanisms. This
argues for the capacity of GSIXII to target mammary
stem-like cells.
GSIXII and the BH3 mimetic ABT-737 strongly synergized
to induce apoptosis in breast cancer cells
As GSIXII induced the expression of proapoptotic Noxa,
which inhibits the survival activity of Mcl-1, we inferred
that its combination with the BH3 mimetic ABT-737,
which targets Bcl-2 and Bcl-xL but not Mcl-1, might
improve apoptosis induction in breast cancer cells. We
observed that combined treatment of breast cancer cell
lines with a suboptimal concentration (that is, 8 μM
GSIXII and 1 μM ABT-737) strongly synergized to induce
cell death (Figure 6A). In these conditions, GSIXII induced
cell-death rates lower than 20%, and ABT-737 induced
death rates lower than 10%, whereas the combination of
both drugs triggered cell-death rates ranging from 50% to
70%. Interestingly, this synergy was also observed when
using the other g-secretase inhibitor DAPT in combination
with ABT-737 (see Additional file 5).
To confirm that Noxa induced on treatment with GSIXII
functions as an inhibitor of Mcl-1, we further evaluated its
interaction with Mcl-1 on GSIXIII treatment, with co-
immunoprecipitation assays. We observed an increase of
the interaction in the GSIXII-treated cells compared with
mock-treated cells (see Additional file 6), demonstrating
that Noxa could sequester Mcl-1 in treated cells. In addi-
tion, the presence of Noxa was greatly decreased in the
Mcl-1-immunodepleted supernatants of GSIXII-treated
cell lysates compared with the corresponding not-depleted
A 
B C 
Figure 2 GSIXII inhibited the Notch signaling pathway in breast cancer cell lines. (A) Breast cancer cell lines were evaluated for Notch1-
ICD expression with immunoblot analysis after treatment by GSIXII 15 μM (+) or mock (-) for 48 hours, by using actin as loading control. (B)
Notch activity was evaluated with CBF1- or mutated CBF1-luciferase promoter assay after treatment by GSIXII, 15 μM, for 24 hours, compared
with mock-treated cells. Represented data are means of CBF1/mutated CBF1 ratios ± SEM of three independent experiments. (C) Cells were
infected with control-GFP (white) or N1ICD-GFP (black) lentivectors and treated with 15 μM GSIXII for 48 hours. Apoptosis of GFP-positive cells
was assessed with Apo 2.7 staining followed by flow-cytometry analysis. Represented data are means ± SEM of three independent experiments.
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ones, indicating that GSIXII-induced Noxa was in the
majority complexed to Mcl-1 (data not shown). Interest-
ingly, the GSIXII and ABT-737 combination led to inhibi-
tion of mammosphere formation in both MCF7 and
BT549 cell lines (Figure 6B). The SAHM1 and ABT-737
combination also decreased mammosphere formation (Fig-
ure 6C). These results argue that potent apoptotic synergy
is induced by g-secretase inhibitors and ABT-737 in stem-
like breast cancer cells, as well as in more-differentiated
cells.
Preclinical evaluation of GSI treatment on human
mammary tumors
The tumor microenvironment is particularly important
for Notch activation. We thus developed a model of 3D
culture of human primary breast tumors in which the
architectural integrity of the tumor, including its micro-
environment, is preserved. In brief, fresh tumors were
rapidly cut into thin slices and incubated in full medium
alone or with drugs (GSIXII+/- ABT-737) for 48 hours.
Tumor slices were then paraffin embedded and analyzed
with IHC for active caspase-3 expression, as a marker of
apoptotic response. We studied a series of 30 consecu-
tive primary tumors from patients with untreated breast
cancer for their sensitivity to the Notch inhibitor GSIXII
with this short-term ex vivo culture of human breast
cancer tissues.
To evaluate the specific response to GSIXII of each
tumor sample, we systematically kept one slice
untreated (to evaluate spontaneous rates of cell death)
A 
B 
Figure 3 GSIXII-induced cell death involved a canonic intrinsic apoptotic pathway. Cell death triggered by GSIXII depended on caspase activity.
Breast cancer cells were pretreated with the pan-caspase inhibitor QVD-OPH (20 μM) before GSIXII treatment at 15 μM for 48 hours and analyzed for
Apo2.7 or Annexin-V staining (more suitable for the MCF7 caspase-3 deficient cell line). Data are the means of positive cells ± SEM; n = 3. (B) Bax
siRNA protected breast cancer cells from GSIXII-induced apoptosis. SiRNA (control (Ct) or Bax)-transfected cells were treated with 15 μM GSIXII before
Apo2.7 immunostaining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.
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and treated another slice from the same tumor with 15
μM GSIXII for 48 hours. Apoptosis was evaluated by
counting the percentage of tumor cells that stained posi-
tive with an anti-active caspase-3 antibody, as evaluated
by IHC analysis of the specimen fixed after incubation
in either condition (Figure 7A); 23 ER-positive and
seven ER-negative tumors were included in this preclini-
cal study.
Investigation of untreated slices showed low cell-death
rates in each tumor, with the mean percentage of active
caspase-3-positive cells in these specimens reaching




Figure 4 Noxa induction triggered GSIXII-induced apoptosis. (A) Breast cancer cells were first transfected by siRNA targeting Bim, Puma, or
Noxa, or control siRNA (siCt), and then treated or not with GSIXII for 48 hours and analyzed with flow cytometry after Apo2.7 immunostaining.
Represented data are the means of positive cells ± SEM, from three independent experiments. SiRNA effects were compared with corresponding
controls. (B) Expression of Noxa protein was assessed with immunoblot after 48 hours of treatment of GSIXII, 15 μM, in indicated breast cancer
cell lines. (C) Noxa mRNA is induced by a GSIXII treatment. Quantitative PCR was performed on cell lines after 48 hours of treatment with mock
(white) or GSIXII (black) and quantified as arbitrary units (au) compared with the mock-treated condition. Represented data are the means of
positive cells ± SEM, from three independent experiments.
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caspase-3-positive cells in GSIXII-treated specimens was
44%. To classify individual tumors according to their
apoptotic response to GSIXII, we arbitrarily defined a
positive threshold above 17% of active caspase-3-positive
tumor cells (corresponding to the highest score in
untreated samples). Of 30 specimens, 24 showed a
response to GSIXII above this threshold and can thus
be considered GSIXII-sensitive tumors (Figure 7B). In
contrast, six of 30 GSIXII-treated specimens showed
cell-death rates that were undistinguishable from those
found in control untreated specimens, which defined
them as GSIXII-resistant tumors. Among sensitive spe-
cimens, we could identify two groups: an intermediate
group of nine tumors that displayed 17% to 40% positive
cells and a highly GSIXII-sensitive group of 15 tumors
showing more than 40% of apoptotic cells under the
conditions used. Importantly, a robust correlation was
noted between the percentage of active caspase-3 tumor
cells and tumor cell integrity, as evaluated with the
standard hematoxylin-eosin-saffron staining performed
on the same sample (see Additional file 7). This strongly
suggests that the effects of GSIXII treatment on the
tumor samples in this ex vivo test predominantly rely on
an apoptotic response, which can be marked and quanti-
fied by caspase-3 activation. In addition, and consistent
with this, Noxa induction could be detected in breast
cancer tissues after GSIXII ex vivo treatment, as shown
in two sensitive tumors (for which we obtained suffi-
cient material to perform immunoblot analysis of
untreated and GSIXII-treated specimens) compared
with the corresponding untreated tissues (Figure 7C).
To evaluate whether ABT-737 treatment might
enhance the apoptotic response of breast tumor samples
to GSIXII induction of cell death, we also regularly trea-
ted, from the same series of tumor samples, one addi-
tional slice with 1 μM ABT-737 and another one with a
combination of GSIXII and ABT-737 before evaluation
of the apoptotic response, as described earlier. Six
A B 
C 
Figure 5 Notch inhibition decreased mammosphere formation. (A) MCF7 and BT549 cell lines were evaluated for their mammosphere-
formation capacity with GSIXII treatment with indicated concentrations. Represented data are the means of MFU% compared with the mock-
treated condition ± SEM, from three independent experiments. (B) The capacity of MCF7 and BT549 cells to form mammospheres at the first
(1st), second (2nd), and third (3rd) generations was assessed in the presence or not of 8 μM GSIXII added at the beginning of the MFU assay.
Represented data are from three independent experiments. Statistical analysis compared mammosphere formation in each serial generation with
its mock-treated control. (C) SiRNA targeting Noxa (black bar) significantly rescued mammosphere formation in BT549 and MCF7 cells on GSIXII
or mock treatment compared with siRNA control (white bar).
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specimens (three ER+ and three ER-) proved to be infor-
mative in these assays, in that their apoptotic response
to GSIXII and ABT-737, used as single agents, gave suf-
ficiently low apoptotic responses, thus allowing synergy
detection. Three of these specimens were GSXII resis-
tant, one intermediate and two GSIXII-sensitive tumors.
Moreover, regarding the ABT-737 response, four speci-
mens were resistant, one was intermediate, and one,
mildly sensitive. In all cases, the combination of ABT-
737 treatment with that of GSIXII led to significantly
enhanced cell death compared with that induced by
each compound alone (Figure 7D). We conclude that at
least some additivity occurs in the effects of the two
compounds in both GSIXII-sensitive samples 44 and 47
and significant synergy in the four remaining tumors,
for which the response to the combined treatment is
higher that the sum of those obtained for each of the
treatment-alone tumors.
Discussion
Aberrant activation of the Notch pathway has been
involved in solid-tumor pathogenesis, triggering protec-
tion against apoptosis or increased cell proliferation, yet
the molecular basis for these effects remains unclear. To
investigate these, and because the g-secretase complex is
a critical step in Notch-pathway activation, we evaluated
the cell-death effects of inhibition of g-secretase activity
by GSIXII in breast cancer. Our results clearly indicate
that GSIXII elicited potent apoptosis in breast cancer
cells and that this effect occurred through the strong
induction of the proapoptotic BH3-only protein Noxa.
Of note, we showed that GSIXII treatment truly
A 
B C 
Figure 6 GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells. Breast cancer cell lines were incubated for 48 hours
with 10 μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining
and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments. (A) Suboptimal
concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were
obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in
combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the
mock-treated condition.
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inactivated the Notch pathway, because it decreased
both the expression of the Notch1 active form (N1ICD)
and the global Notch transcriptional activity. Impor-
tantly, N1ICD overexpression rescued breast cancer
cells from GSI-induced apoptosis. These latter results
strongly argue that the potent cell-death effect of GSIXII
relies on the inhibition of Notch processing into its
active form. We cannot formally rule out, however, that
additional effects, such as that on proteasome activity
previously reported for the structurally related GSI-I
[29], contribute to cell-death induction, but preliminary
data with DAPT, that was described as a specific g-
secretase inhibitor devoid of inhibitory effect on protea-
some activity by Han and colleagues [29], could also
sensitize breast cancer cells to cell death. Importantly,
the cytotoxic effects of GSIXII could be detected not
only in the bulk of breast cancer cell lines but also in
their stem cell-like compartment. This effect most likely
results from Notch inhibition, as it was recapitulated by
the Notch transcription factor inhibitor SAHM1. Intri-
guingly, this compound was more effective, in our
hands, on this subpopulation enriched in self-renewing
cells than on the bulk of cell lines. This may be due to a
weak ability of the peptide to enter cells and/or to a
higher dependency on Notch signaling of the stem-like
cells compartment compared with the bulk population.
Such a specific effect of Notch inhibition on mammo-
sphere cultures has been observed by Farnie and
A B 
C D 
Figure 7 GSIXII induced apoptosis in primary breast tumor cells in ex vivo assay. Active caspase-3 immunostaining analyzed with
immunohistochemistry in one of the human breast tumors 48 hours after 15 μM GSIXII treatment or untreated (Ct). Magnification, ×200 and
×400. (A) 23 ER+ (Δ) or 7 ER- (▲) primary human tumor samples were cultured 48 hours with 15 μM GSIXII or not treated (Ct), as described in
Materials and methods, and then analyzed for active caspase-3 with immunohistochemistry. Data are represented as percentage of tumoral cells
positive for active caspase-3 immunostaining in each specimen. (B) Noxa expression was induced in breast tumor samples after 48-hour GSIXII
treatment compared with the untreated condition, as shown in two samples assessed with immunoblot analysis. (C) The GSIXII and ABT-737
combination enhanced apoptosis triggering in breast cancer tumors. Six human primary tumor samples (three ER+ and three ER-) were cultured
for 48 hours with or without 15 μM GSIXII in combination with 1 μM ABT 737 or not for 48 hours, in ex vivo assay. The percentage of active
caspase-3-positive tumoral cells was then established with immunohistochemistry. A one-way ANOVA test performed on the presented cohort of
tumors indicates that the combination (GSIXII+ABT-737) was significantly better than either GSIXII or ABT-737 single treatment (** and ***,
respectively).
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colleagues [30,31]. Importantly, freshly explanted human
breast cancer cells maintained in their microenviron-
ment are also sensitive to induction of apoptosis by
GSIXII. In addition, simultaneous treatment with
GSIXII and the Bcl-2/Bcl-xL inhibitor ABT-737 led to
synergistic effects in all three paradigms.
Altogether, our results strongly argue for the use of
the g-secretase inhibitors in breast cancer therapy, espe-
cially in combination with Bcl-2/Bcl-xL inhibition,
which may help to reduce the dose of GSI used.
In an attempt to define molecular mechanisms
involved in apoptosis triggered by GSIXII treatment, we
first demonstrated that it was related to Bax and the
caspase-dependent pathway. We then identified the
BH3-only Bcl-2 family member Noxa as a pivotal actor.
Indeed, its expression was strongly induced on GSIXII
treatment, in breast cancer cell lines as well as in
human primary breast tumors. Moreover, its knockdown
by RNA interference potently blocked apoptosis in
breast cancer cell lines, as previously observed in mela-
noma cell lines with GSI-I treatment [32]. We also
detected Noxa mRNA accumulation on GSIXII treat-
ment, arguing for an increase of its gene transcription
rather than stabilization of the protein.
Previous studies have indicated Bcl-2 family members
as major regulators of apoptosis triggering by Notch
inhibition. Some reported the decrease of antiapoptotic
Bcl-2 members, such as Bcl-xL, on GSI treatment in
cancer cells [14,16]. Others described inefficient p53
response after treatment by potent p53 activators, such
as genotoxic drugs acquired on Notch activation [17].
Of note, activated Notch1 could suppress Noxa expres-
sion even in mutated p53 cells, possibly through the
regulation of E2F-1 [7]. Currently, and in contrast to the
antiapoptotic gene survivin that is a direct target of
Notch [15], no direct transcriptional regulation of Bcl-2
family genes by Notch has been reported. However,
numerous regulators of Noxa expression have been
described, among them p53, c-myc, and E2F-1 [reviewed
in [33]], and further experiments are needed to investi-
gate whether these, or additional factors, are involved in
Noxa induction on Notch inhibition.
Importantly, Noxa specifically inhibits the survival
activity of Mcl-1 and can also target it for proteosomal
degradation [34]. This presumably occurs in GSIXII-
treated cells, because we found that induced Noxa
potently binds to Mcl-1. This event is a prerequisite for
cell death induced by various stimuli (UV, cytokine
deprivation, or treatment with anticancer agents)
[reviewed in [33]]. Thus our work establishes that
GSIXII, which triggers Noxa expression, functions as an
indirect inhibitor of one key survival protein, Mcl-1.
Because evasion of apoptosis has been recognized as
one of the hallmarks of cancer, pharmacologic inhibition
of antiapoptotic proteins is a potential strategy to
restore apoptosis function in cancer cells. Several mole-
cules, including ABT-737, have been designed to mimic
the binding of BH3-only proteins to the hydrophobic
groove of antiapoptotic proteins, blocking their activity.
ABT-737 nevertheless binds preferentially to Bcl-2 and
Bcl-xL but not to Mcl-1. Thus ABT-737 is ineffective in
killing tumor cells expressing high levels of Mcl-1 com-
pared with those of Bcl-2/Bcl-xL [35].
Breast cancer cells often express high levels of Bcl-2,
Bcl-xL, and/or Mcl-1 [36]. Therefore, a rationale exists
to use BH3 mimetics to circumvent apoptosis resistance
in these cancers. We recently reported, in particular,
that Mcl-1 participates in survival maintenance of breast
cancer cells, at the very least in that of the HER2-ampli-
fied subtype [23]. Thus, combining Bcl-2/Bcl-xL and
Mcl-1 inhibition by ABT-737 and GSIXII, respectively,
should restore apoptosis sensitivity efficiently and affect
survival maintenance, in breast cancer cells. Our results
are consistent with this and clearly indicate that ABT-
737 and GSIXII co-treatment led to synergistic apopto-
sis in breast tumors, suggesting the potential use of this
combination to overcome cellular resistance. Interest-
ingly, previous reports indicated that GSI treatment sen-
sitized cancer cells to other chemotherapeutics drugs,
such as oxaliplatin or 5-FU in colon cancer cells [16]. In
the same line, the combination of BH3 mimetics with
potent inducers of Noxa, such as vinblastin [37] or cis-
platin [38], induced cancer cell sensitization to
apoptosis.
Mammary stem cells, defined by indefinite self-replica-
tion that ensures tissue self-renewing by asymmetric cell
division and generation of progenitor cells, have been
isolated from both normal breast tissues and breast
tumors [10]. This cell population exhibits an inherent
capacity to form clonal mammospheres in suspension in
in vitro assays, and in breast cancer stem cells, to initi-
ate tumors in in vivo assays. Importantly, these cells
show resistance to toxic agents [39]. Indeed, conven-
tional chemotherapy often kills a majority of differen-
tiated cancer cells but spares cancer stem cells, thus
probably participating in cancer recurrence. We assessed
this cellular compartment by using mammosphere-for-
mation assay and showed that inhibition of Notch sig-
naling, by using either GSIXII or SAHM1, successfully
decreased mammosphere formation. This highlights the
importance of the Notch pathway in mammary stem
cell maintenance, as previously reported in breast cancer
stem-like cells [40] or in normal mammary stem cells
[10]. In addition, we found evidence that Noxa is
involved in the effects of GSIXII, at least in part,
because its knockdown significantly rescued mammo-
sphere formation in GSIXII-treated cells. However, we
cannot exclude the involvement of other mechanisms in
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the process, because this rescue was partial. Of particu-
lar interest, the simultaneous treatment with GSIXII and
ABT-737 strongly impaired mammosphere formation.
These results revealed that the Bcl-2 family of proteins
might play an important role in maintaining the survival
of breast cancer stem-like cells. Interestingly, this obser-
vation is supported by a recent report that shows that
the co-silencing of Bcl-2, Bcl-xL, and Mcl-1 in breast
cancer cell lines potently reduced mammosphere forma-
tion [41]. Practically, targeting breast cancer stem-like
cells with BH3-mimetics should improve therapeutic
outcomes.
Recent data suggest that Notch signaling is also
important in the tumor microenvironment, as observed
in myeloma [42] or head and neck squamous carcinoma
cells [43]. The 3D short-term ex vivo model we devel-
oped, similar to the one described by van der Kuip and
colleagues [44], allowed correct maintenance of intact
breast tumoral tissues where cells remained viable and
still proliferated because of sufficient diffusion of oxygen
or nutrients. This assay preserves specific interactions
between tumor cells and surrounding nontumoral tissue
components and provides a powerful, rapid, and repro-
ducible tool for studying the differential responses of
individual tumors (and their various components) to
specific drugs. Our results clearly demonstrate that GSI
treatment is efficient in breast cancer cells embedded in
their microenvironment.
We evaluated a series of 30 human primary breast
tumors in the ex vivo assay and found evidence that 24
tumors exhibited high levels of caspase-3 activity on GSI
treatment. Crucially, this method can be used to predict
tumor sensitivity to drugs in a patient-specific manner
and to help to identify patients who could benefit from
the specific therapy. Moreover, combining GSIXII treat-
ment with ABT-737 treatment led to a synergistic proa-
poptotic effect in six tumors tested. Among them, three
were resistant to GSIXII, and four were resistant to
ABT-737, each used as single agent. Thus, these results
strongly argue for potent proapoptotic cooperation
between GSIXII and ABT-737 in breast cancer cells
maintained in their microenvironment.
Conclusions
Altogether, our data provide strong evidence that g-
secretase inhibition triggers potent apoptosis in breast
cancer cells. Moreover, the induction of Noxa expres-
sion played a major role in this process. Combining
GSIXII treatment with ABT-737 strongly enhanced the
apoptotic response in breast cancer cells, especially in
tumors for which both molecules used as single agents
led to a moderate proapoptotic effect. Thus, our data
suggest that g-secretase inhibition might offer a potent
novel approach to treating breast cancers. Experimental
treatments with Notch inhibitors in animal models were
very promising [45]. However, they resulted in serious
gastrointestinal side effects or immunosuppression [46].
A therapeutic window may exist if GSI could be given
for short periods or in smaller doses. On the basis of
our data, we propose that combining g-secretase inhibi-
tion with Bcl-2/Bcl-xL targeting, might allow us to use
concentrations of GSI under the side-effect limit in
breast cancer therapy.
Additional material
Additional file 1: GSIXII treatment induced Annexin-V-positive
staining in breast cancer cells. Cells were incubated with 15 μM GSIXII
or with DMSO for 48 hours, and then assessed for Annexin-V expression
with flow cytometry.
Additional file 2: Proteasome activity inhibition and apoptosis
induction on GSIXII or bortezomib treatment did not correlate in
breast cancer cell lines. Proteolytic activity of 20S proteasome was
quantified in breast cancer cell lines treated with GSIXII (15 μM) or
bortezomib (10 nM) with the fluorimetric substrate assay by using the
substrate Suc-Leu-Leu-Val-Leu-AMC, according to the manufacturer’s
recommendation (Tebu Bio, Le Perray-en-Yvelines, France) (A). Apo2.7-
positive cells were evaluated on 15 μM GSIXIII treatment or 10 nM
bortezomib for 48 hours, as previously described (B). Data are
represented as percentage mean of inhibition compared with control
(mock-treated) cells ± SEM; n = 3.
Additional file 3: BH3-only proteins expression in MDAMB231 cells
after RNA interference. Extinction of proteins expression was evaluated
with immunoblot analysis after siRNA transfection in MDAMB231 for Bim
and Puma (A) and Noxa on GSIXII treatment or not for 48 hours (B).
Additional file 4: GSIXII treatment did not induce other Puma and
Bim BH3-only proteins. Expression of Noxa, Puma, and Bim proteins
was assessed with immunoblot after 48 hours of treatment of GSIXII in
MDAMB231 cells. *Nonspecific band.
Additional file 5: DAPT synergized with ABT-737 to trigger
apoptosis in breast cancer cells. MDAMB231 cells were incubated for
48 hours with 10 μM DAPT (Sigma, Saint-Quentin Fallavier, France) in
combination or not with ABT-737, 1 μM. Then apoptosis was evaluated
with Apo2.7 immunostaining and flow-cytometry analysis. Represented
data are the means of positive cells ± SEM, from three independent
experiments.
Additional file 6: Noxa co-immunoprecipitated mainly with Mcl-1
after GSIXIII treatment. Cells were treated for 48 hours with GSIXII and
QVD-OPH (to avoid cell death and obtain sufficient protein material in
treated cells) before lysis in CHAPS buffer. Whole lysates were incubated
overnight with the capture antibody (Mcl-1 S19 clone; Santa Cruz (Santa
Cruz, USA), and then immunocomplexes were captured by using protein
G-magnetic beads according to manufacturer’s instructions (Millipore,
Molsheim, France), in GSIXII-treated or untreated indicated cells. The
immunoprecipitates were analyzed for the presence of Mcl-1 and Noxa
proteins with immunoblotting.
Additional file 7: Correlation between HES and active caspase-3 IHC
on GSIXII-treated tumors. Each specimen was scored for active
caspase-3 IHC and HES staining, allowing cell-morphology analysis. Active
caspase-3 was scored as percentage of positive tumor cells. HES score
was established in three groups, depending on the percentage of cells
with altered morphology: group 1 (< 25%), group 2 (25% to 50%), and
group 3 (> 50%).
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